Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Mallinckrodt plc (MNK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Second Quarter 2023 Financial Results and Reaffirms Full Year Guidance Reports Second Quarter Net Sales of $475.0 Million, Reflecting a 1.3% Growth on a Reported and Constant Currency Basis Compared to the Prior Year Quarter"
05/09/2023 8-K Quarterly results
Docs: "Mallinckrodt plc Reports First Quarter 2023 Financial Results and Reaffirms Full Year Guidance Advanced Launch of Terlivaz® with Rapid and Successful Uptake in Hospital Formulary Access and Continued Medical Community Interest"
11/08/2022 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Third Quarter 2022 Financial Results and Reaffirms Guidance Launched Terlivaz® Following U.S. Food and Drug Administration Approval in September&#59; Submitted U.S. FDA Premarket Notification Application for Next-Generation Delivery System of INOmax®"
08/11/2022 8-K Quarterly results
08/04/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "November __, 2019",
"Mallinckrodt plc Reports Earnings and Pipeline Advancements for the Third Quarter 2019 and Raises Adjusted Diluted Earnings Per Share Guidance Range for 2019"
08/06/2019 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Strong Results in Second Quarter 2019, Raises Adjusted EPS Guidance for 2019, and Announces Suspension of Specialty Generics Spin-off"
05/07/2019 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Strong Growth in First Quarter 2019 Results, Raises Guidance for 2019, and Continues to Make Significant Advancements in Pipeline and Data Generation"
02/26/2019 8-K Quarterly results
11/06/2018 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Third Quarter 2018 Results and Raises Earnings Guidance for 2018 -- Net sales of $640.0 million, up 6.6%, or 6.7% on a constant-currency basis -- -- GAAP 1 diluted income per share from continuing operations of $1.21; adjusted diluted earnings per share of $2.10 -- -- Third quarter operating cash flow of $219.3 million, free cash flow of $193.1 million; year-to-date operating cash flow of $481.1 million, free cash flow of $387.8 million -- -- Third quarter debt reduced by $170.6 million; $630.7 million total debt reduction since end of first quarter -- -- Full year 2018 adjusted diluted earnings per share guidance increased to $7.00 to $7.20 --"
08/07/2018 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Second Quarter 2018 Results and Raises Guidance for 2018 -- Net sales of $631.7 million, up 5.3%, or 5.0% on a constant-currency basis -- -- GAAP 1 diluted loss per share from continuing operations of $0.34, adjusted diluted earnings per share of $1.78 -- -- Second quarter operating cash flow of $244.0 million, free cash flow of $211.2 million; debt reduced by $460.2 million in the period -- -- R&D expenses of $81.3 million or 12.9% of net sales, supporting increased pipeline investment and data generation for inline portfolio -- -- Full year 2018 guidance increased; net sales growth range raised to 4% to 7% ; adjusted diluted earnings per share raised to $6.50 to $6.90 --"
05/08/2018 8-K Quarterly results
Docs: "Mallinckrodt plc Reports First Quarter 2018 Results -- Net sales of $572.6 million driven by strong hospital products performance -- -- GAAP 1 diluted loss per share from continuing operations of $0.50, adjusted diluted earnings per share of $1.31 -- -- Closed Sucampo acquisition; completed move of Specialty Generics Disposal Group to discontinued operations -- -- Full year free cash flow generation expected to be approximately $500 million --"
02/27/2018 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Fourth Quarter and Fiscal 2017 Results, Announces 2018 Guidance and Sets 2018 Strategic Priorities -- Fourth quarter net sales of $792.3 million; GAAP 1 diluted earnings per share from continuing operations of $17.40, adjusted diluted earnings per share of $2.01 -- -- Fiscal 2017 net sales of $3.222 billion; GAAP diluted earnings per share from continuing operations of $18.09, adjusted diluted earnings per share of $7.49 -- -- Fourth quarter operating cash flow of $278.8 million, free cash flow of $244.0 million; annual operating cash flow of $727.3 million, free cash flow of $541.2 million -- -- $1.5 billion one-time benefit in quarter resulting from legal entity reorganization and tax reform -- -- 9.4 million shares, or ~10% of company repurchased in the quarter ...",
"Historical Net Sales Information"
11/07/2017 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Earnings Results for Third Quarter of Fiscal 2017 -- Net sales of $793.9 million negatively impacted by 6 to 9 percentage points versus 14-week prior year period; H.P. Acthar ® Gel also impacted by lower volumes; Hospital results solid; Specialty Generics segment consistent with guidance -- -- GAAP 1 diluted earnings per share from continuing operations of $0.66; adjusted diluted earnings per share of $1.97 -- -- Third quarter operating cash flow of $226.0 million; free cash flow of $176.3 million -- -- Planned acquisition of Ocera continues to build pipeline, focusing on severe and critical conditions -- -- Legal entity reorganization expected to create one-time tax benefit in excess of $800 million in the fourth quarter of 2017, primarily reducing interest-bearin..."
08/08/2017 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Earnings Results for Second Quarter of Fiscal 2017 -- Net sales of $824.5 million -- -- Specialty Brands segment net sales increased 0.9%, 1.2% on a constant-currency basis -- -- Specialty Generics segment net sales decreased 18.0%, 17.8% on a constant-currency basis -- -- GAAP 1 diluted earnings per share from continuing operations of $0.72; adjusted diluted earnings per share of $1.85 -- -- Second quarter operating cash flow of $319.9 million; free cash flow of $270.9 million -- -- Adjusted diluted earnings per share guidance reiterated at $7.40 to $8.00 for fiscal 2017 --"
05/08/2017 8-K Form 8-K - Current report
11/29/2016 8-K Form 8-K - Current report
08/02/2016 8-K Form 8-K - Current report
05/03/2016 8-K Form 8-K - Current report
02/02/2016 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Fiscal 2016 First Quarter Results"
11/23/2015 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Financial Results For Fiscal 2015 Fourth Quarter and Full Year"
08/04/2015 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Fiscal 2015 Third Quarter Financial Results • Third quarter net sales up 47.8% to $965 million • Third quarter diluted earnings per share of $0.49 • Third quarter adjusted diluted earnings per share up 70.8% to $2.05"
05/05/2015 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Fiscal 2015 Second Quarter Financial Results; Raises Full Year 2015 Guidance"
02/03/2015 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Fiscal 2015 First Quarter Financial Results"
11/19/2014 8-K Quarterly results
Docs: "MALLINCKRODT PLC REPORTS FISCAL 2014 FOURTH QUARTER AND FISCAL 2014 FINANCIAL RESULTS"
08/07/2014 8-K Quarterly results
Docs: "MALLINCKRODT PLC REPORTS FISCAL 2014 THIRD QUARTER FINANCIAL RESULTS; UPDATES FULL-YEAR 2014 GUIDANCE, INCREASING NET SALES AND ADJUSTED DILUTED EARNINGS PER SHARE"
05/08/2014 8-K Quarterly results
Docs: "MALLINCKRODT PLC REPORTS FISCAL 2014 SECOND QUARTER FINANCIAL RESULTS; INCREASES FULL-YEAR 2014 GUIDANCE"
02/06/2014 8-K Quarterly results
Docs: "Mallinckrodt plc Reports Fiscal 2014 First Quarter Financial Results And Revises Full-Year Guidance • First quarter net sales of $540 million, up 8.0% on an operational growth basis • First quarter adjusted diluted earnings per share of $0.88 • Guidance increased on full-year revenue and full-year adjusted diluted earnings per share"
12/02/2013 8-K/A Form 8-K/A - Current report [Amend]
11/07/2013 8-K Form 8-K - Current report
08/09/2013 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy